Drug labels would have to disclose true manufacturing origin under new bill

What does this do?

This bill would require labels on active pharmaceutical ingredients and finished drugs to identify the "original manufacturer" — the last facility that did substantial manufacturing — along with a unique facility identifier. This information could appear on the label itself or be accessible via barcode, QR code, or online portal, with paper disclosure available on request. It also exempts compliant drugs from separate customs country-of-origin marking rules.

Who does it affect?

Drug manufacturers, packagers, and distributors would face new labeling and disclosure requirements, particularly those using overseas ingredients or manufacturing; pharmacists, doctors, and consumers would gain more visibility into drug origins.

Why does it matter?

Companies relying on foreign manufacturing or ingredients would need to change labeling practices and disclosure systems, and the FDA must first write implementing regulations before requirements take effect.

Where does it stand?